Compare Moderna, Inc. (MRNA) vs Upstart Holdings Inc (UPST) Price & Performance

Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.

Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.

Upstart Holdings (UPST) trades at $29.27, down 0.81% on the day, with a bearish technical signal but improving fundamentals. The company reported a net income of $53.60 million in 2025, marking a significant turnaround from prior losses. Recent news highlights AI-driven lending growth and a $600 million funding deal with Neuberger Berman, though quarterly earnings have been mixed with a recent miss in Q1 2026.

The stock presents a high-risk, high-reward opportunity, supported by analyst consensus targets near $42.00 but challenged by volatile cash flows and rising debt. Key risks include execution on new loan products and macroeconomic sensitivity, while institutional sentiment remains divided with a 45% buy rating. Near-term direction hinges on Q2 2026 results due August 4, 2026.